Actively Recruiting
Therapeutic Orientation Test in Thrombotic Microangiopathy
Led by University Hospital, Montpellier · Updated on 2025-07-23
100
Participants Needed
20
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich block alternative complement pathway activation. To rise treatment success, Eculizumab introduction should be as early as possible. In some secondary HUS (infection, drugs…) complement is also involved as "second-hit". To date, there is no tool to confirm complement involvement in a HUS at diagnosis stage. This study suggest to evaluate a therapeutic orientation test, in order to determine the complement implication in HUS diagnosis. The test evaluates the complement deposits on endothelial cell surface in vitro, compared to a normal human serum. In order to determine the test performance, first the positive or negative results will be compared to the HUS clinical evolution, treated or not by the clinician with Eculizumab. Second, the test results will be compared to the presence of alternative complement pathway regulation abnormalities.
CONDITIONS
Official Title
Therapeutic Orientation Test in Thrombotic Microangiopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of thrombotic microangiopathy (TMA) with mechanical hemolytic anemia, undetectable haptoglobin, and LDH greater than 1.5 times the normal limit
- Presence of thrombocytopenia
- Acute kidney injury due to TMA affecting native kidney or post-transplantation
You will not qualify if you...
- Disseminated intravascular coagulation (DIVC) patients
- Plasma exchange treatment within 1 month before sample collection
- Treatment with Eculizumab before sample collection
- Lack of consent to participate
- Not covered by social security
- Pregnancy or breastfeeding
- Patient under legal guardianship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
CHU de Bordeaux
Bordeaux, France
Actively Recruiting
2
Site Médipôle Cabestany
Cabestany, France
Not Yet Recruiting
3
Centre Nephrocare Castelnau-le-Lez
Castelnau-le-Lez, France
Not Yet Recruiting
4
CHU de Grenoble
Grenoble, France
Actively Recruiting
5
CHU de Lille
Lille, France
Actively Recruiting
6
CHU de Limoges
Limoges, France
Actively Recruiting
7
APHM-Hôpital de la Conception
Marseille, France
Actively Recruiting
8
Montpellier University Hospital
Montpellier, France
Actively Recruiting
9
CHU de Nantes
Nantes, France
Actively Recruiting
10
HPGN- Narbonne
Narbonne, France
Not Yet Recruiting
11
CHU de Nice
Nice, France
Actively Recruiting
12
CHU de Nîmes
Nîmes, France
Actively Recruiting
13
APHP-Hôpital Tenon
Paris, France
Actively Recruiting
14
Hôpital Paris Necker
Paris, France
Actively Recruiting
15
CH de Perpignan
Perpignan, France
Actively Recruiting
16
CHU de Poitiers
Poitiers, France
Actively Recruiting
17
CHU de Rouen
Rouen, France
Actively Recruiting
18
Hôpitaux Universitaires de Strasbourg
Strasbourg, France
Actively Recruiting
19
CHU de Toulouse
Toulouse, France
Actively Recruiting
20
CHRU Tours
Tours, France
Actively Recruiting
Research Team
M
Moglie LE QUNITREC-DONNETTE, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here